Pharvaris N.V. (PHVS), a clinical-stage company developing novel, oral therapies to treat and prevent hereditary angioedema attacks, is slated to make a poster presentation at the Western Society of Allergy, Asthma & Immunology Annual Meeting on Feb.4, 2024.
One of the posters is about the efficacy and safety of bradykinin B2 receptor antagonism with Deucrictibant immediate-release capsule (also known as PHVS416) for the treatment of hereditary angioedema (HAE) attacks based on findings from RAPIDe-1 trial.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com